- 期刊
Rucaparib治療復發性卵巢癌的檢視
The Role of Rucaparib in the Treatment of Patients with Recurrent Ovarian Cancer
摘要
根據最近的研究認為，PARP可用來治療同源重組不足的癌症病患，因PARP可作為鹼基修補酵素，如抑制其作用可使兩股DNA受傷，使得腫瘤細胞死亡。Rucaparib乃一小分子的PARP-1、PARP-2和PARP-3抑制劑，臨床上可抑制卵巢癌或其它實心腫瘤的生長，特別是有BRCA1/2突變和同源重組不足的上皮性卵巢癌，副作用可被接受。美國食品藥物管理局已通過，rucaparib可用在治療BRCA突變或經過兩次化學治療的晚期卵巢癌。
並列摘要
Poly(ADP-ribose) polymerase(PARP) inhibitors have primarily been studied as monotherapy in cancers with homologous recombination deficiencies based on an early understanding of PARP as a base excision repair enzyme and the idea that abrogation of two DNA repair pathways damages rapidly dividing cancer cells. Rucaparib is a potent small-molecule inhibitor of PARP-1, PARP-2 and PARP-3 that has shown clinical activity in ovarian carcinoma as well as other types of solid tumors; it has been extensively investigated in epithelial ovarian cancer harboring BRCA1/2 mutations or homologous recombinat deficiencies. Rucaparib has an acceptable toxicity. It has recently received FDA (The Food and Drug Administration) approval for patients with deleterious BRCA mutation (germline or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies.